Valeant Pharmaceuticals’ (VRX) Siliq (brodalumab) is an inhibitor of human interleukin-17 receptors (or IL-17RA) used for the treatment of adult individuals with moderate-to-severe plaque psoriasis who are subjects of systemic therapy or phototherapy and didn’t respond or lost the response to other systemic therapies.
In October 2017, Valeant Pharmaceuticals presented the results of its pivotal Phase 3 long-term extension AMAGINE-2 trial. In the trial, Siliq demonstrated sustained high levels of skin clearance for more than two years in individuals with moderate-to-severe psoriasis. Patients on any dose of Siliq at the induction phase and Siliq over the maintenance and long-term extension (or LTE) phases showed similar response rates. Among the patients on Siliq in the induction phase and LTE phases at week 120, 59.0% of them demonstrated a PASI (Psoriasis Area and Severity Index) 100, or complete clearance, and 76.4% of them demonstrated a PASI 90. At 52 weeks, 63.4% of the same group had a PASI 100, and 58.9% had PASI 90 response rates. At 120 weeks, Siliq continued to show a consistent safety profile as it did at 52 weeks.
In the Phase 3 AMAGINE-1 trial, Valeant Pharmaceuticals evaluated the safety and efficacy of Siliq in patients with previous exposure to ustekinumab. Among the patients receiving continuous Siliq therapy, 65.2% who were ustekinumab-naïve achieved PASI 100, while 76.5% of them who had a prior ustekinumab experience achieved PASI 100. Among the patients receiving continuous Siliq therapy, 75.8% who were ustekinumab-naïve achieved PASI 90, and 88.2% with previous ustekinumab experience achieved PASI 100.
Growth in sales for Siliq could boost the stock of the Vanguard Total International Stock ETF (VXUS). Valeant Pharmaceuticals makes up ~0.02% of VXUS’s total portfolio holdings.